CLINICAL TRIALS PROFILE FOR PENICILLIN

505(b)(2) Clinical Trials for Penicillin

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Indication	NCT05069974 ↗	Alternative Antibiotics for Syphilis	Recruiting	Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia	Phase 3	2021-10-01	The Trep-AB clinical trial will test the efficacy of an investigational neuropenetrative drug, Linezolid (LZD), compared to standard treatment, Benzathine penicillin G (BPG), for early syphilis in humans. The overarching idea of the work proposed herein is to investigate the use of LZD to treat syphilis, conducting a randomized controlled clinical trial to evaluate this new indication of a known antibacterial agent. It is estimated to include 360 participants.

All Clinical Trials for Penicillin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000585 ↗	Penicillin Prophylaxis in Sickle Cell Disease (PROPS)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1983-08-01	To determine whether the regular daily administration of oral penicillin would reduce the incidence of documented infection due to Streptococcus pneumoniae in children with sickle cell anemia.
NCT00000648 ↗	A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals	Completed	Hoffmann-La Roche	N/A	1969-12-31	To provide information on the response of HIV infected, neurosyphilis patients to the currently recommended treatment for neurosyphilis; to determine whether possible co-infection with both HIV and syphilis makes more difficult the diagnosis of syphilis; to explore the usefulness of an alternative treatment which, if effective, would permit outpatient treatment for neurosyphilis that until now required prolonged hospitalization. Studies suggest that syphilis treatment failures may be more common in HIV infected patients than in patients without HIV infection and that treatment failures occur due to and/or are displayed as central nervous system (CNS) involvement. Very little is known about the best treatment course for neurosyphilis in patients who are also infected with HIV.
NCT00000648 ↗	A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To provide information on the response of HIV infected, neurosyphilis patients to the currently recommended treatment for neurosyphilis; to determine whether possible co-infection with both HIV and syphilis makes more difficult the diagnosis of syphilis; to explore the usefulness of an alternative treatment which, if effective, would permit outpatient treatment for neurosyphilis that until now required prolonged hospitalization. Studies suggest that syphilis treatment failures may be more common in HIV infected patients than in patients without HIV infection and that treatment failures occur due to and/or are displayed as central nervous system (CNS) involvement. Very little is known about the best treatment course for neurosyphilis in patients who are also infected with HIV.
NCT00001359 ↗	Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup)	Completed	National Institute of Mental Health (NIMH)	Phase 2	1993-04-01	A subgroup of patients with childhood-onset obsessive-compulsive disorder (OCD) and/or tic disorders has been identified who share a common clinical course characterized by dramatic onset and symptom exacerbations following group A beta-hemolytic streptococcal (GABHS) infections. This subgroup is designated by the acronym PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections). There are five clinical characteristics that define the PANDAS subgroup: presence of OCD and/or tic disorder; prepubertal symptom onset; sudden onset or abrupt exacerbations (relapsing-remitting course); association with neurological abnormalities (presence of adventitious movements or motoric hyperactivity during exacerbations); and temporal association between symptom exacerbations and GABHS infections. In this subgroup, periodic exacerbations appear to be triggered by GABHS infections in a manner similar to that of Sydenham's chorea, the neurological variant of rheumatic fever. Rheumatic fever is a disorder with a presumed post-streptococcal autoimmune etiology. The streptococcal pathogenesis of rheumatic fever is supported by studies that have demonstrated the effectiveness of penicillin prophylaxis in preventing recurrences of this illness. A trial of penicillin prophylaxis in the PANDAS subgroup demonstrated that penicillin was not superior to placebo as prophylaxis against GABHS infections in these children, but this outcome was felt to be secondary to non-compliance with treatment, and there was no decrease in the number of neuropsychiatric symptom exacerbations in this group. In a study comparing azithromycin and penicillin, both drugs were completely effective in preventing streptococcal infections - there were no documented titer elevations during the year-long study period for children taking either penicillin or azithromycin. Comparable reductions in the severity of tics and obsessive-compulsive symptoms were also observed. Thus, penicillin was not performing as an "active placebo" as originally postulated, but rather provided effective prophylaxis against Group A beta-hemolytic streptococcal. Both azithromycin and penicillin appear to be effective in eliminating GABHS infections, and reducing neuropsychiatric symptom severity; thus, between-group differences are negligible. Since increasing the "n" to demonstrate superiority of one prophylactic agent over another would be impractical, we have amended the study design to address two issues: 1. To determine if antibiotics prophylaxis against GABHS infections is superior to placebo in prolonging periods of remission among children in the PANDAS subgroup. 2. To determine if antibiotics prophylaxis against GABHS infections is superior to placebo in improving overall symptom severity for obsessive-compulsive symptoms and tics among children in the PANDAS subgroup. Because penicillin has a narrower therapeutic index and is less expensive than azithromycin, it is the preferable prophylactic agent. Further, penicillin (250 mg orally twice a day) has a long history of providing safe and effective prophylaxis for rheumatic fever and is the first line oral therapy recommended by the American Heart Association. Thus, penicillin has been chosen as the prophylactic antibiotic in the present study. Blister packs are used to increase compliance and to allow for easier documentation of missed doses.
NCT00002682 ↗	Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach	Completed	National Cancer Institute (NCI)	Phase 2	1995-08-10	RATIONALE: Antibiotic therapy and antacids are used to treat Helicobacter pylori infection of the stomach. These treatments may also have an effect on gastric MALT lymphoma of the stomach. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy with amoxicillin, clarithromycin, tetracycline, and metronidazole plus antacids in patients with MALT lymphoma of the stomach.
NCT00002682 ↗	Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach	Completed	M.D. Anderson Cancer Center	Phase 2	1995-08-10	RATIONALE: Antibiotic therapy and antacids are used to treat Helicobacter pylori infection of the stomach. These treatments may also have an effect on gastric MALT lymphoma of the stomach. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy with amoxicillin, clarithromycin, tetracycline, and metronidazole plus antacids in patients with MALT lymphoma of the stomach.
NCT00003824 ↗	S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer	Terminated	National Cancer Institute (NCI)	Phase 3	1999-04-01	RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether ciprofloxacin is more effective than cephalexin in preventing cancer recurrence in patients who are undergoing surgery to treat bladder cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of ciprofloxacin with that of cephalexin in preventing recurrence of cancer in patients who are undergoing surgery for bladder cancer.

Clinical Trial Conditions for Penicillin

Condition Name

Condition Name for Penicillin
Intervention	Trials
Syphilis	12
Penicillin Allergy	11
Helicobacter Pylori Infection	10
Pneumonia	7

Condition MeSH

Condition MeSH for Penicillin
Intervention	Trials
Infections	33
Infection	25
Communicable Diseases	24
Syphilis	17

Clinical Trial Locations for Penicillin

Trials by Country

Trials by Country for Penicillin
Location	Trials
United States	206
China	25
Canada	21
Australia	18
Israel	11

Trials by US State

Trials by US State for Penicillin
Location	Trials
California	15
Ohio	12
New York	12
Texas	11
North Carolina	9

Clinical Trial Progress for Penicillin

Clinical Trial Phase

Clinical Trial Phase for Penicillin
Clinical Trial Phase	Trials
PHASE4	11
PHASE3	6
PHASE2	5

Clinical Trial Status

Clinical Trial Status for Penicillin
Clinical Trial Phase	Trials
Completed	89
RECRUITING	37
Not yet recruiting	27

Clinical Trial Sponsors for Penicillin

Sponsor Name

Sponsor Name for Penicillin
Sponsor	Trials
World Health Organization	7
National Institute of Allergy and Infectious Diseases (NIAID)	6
University of Oxford	5

Sponsor Type

Sponsor Type for Penicillin
Sponsor	Trials
Other	379
Industry	26
NIH	11

Penicillin Market Analysis and Financial Projection

Last updated: April 25, 2026

Penicillin (Natural Penicillin): Clinical Trial Landscape, Market Analysis, and Forward Projection

What is PENICILLIN in this context?

“Penicillin” is a legacy antibacterial class rather than a single modern small-molecule asset with one definable development timeline. Commercially, it covers multiple related members (most notably benzylpenicillin/penicillin G and phenoxymethylpenicillin/penicillin V) and has long-standing generic availability across most major markets. For business planning, the commercially actionable “drug” unit is the market for penicillin-class antibacterials, not a single late-stage pipeline candidate.

The question of “clinical trials update” for penicillin is therefore best interpreted as:

• ongoing clinical use evidence (e.g., quality, resistance surveillance, stewardship outcomes), and
• newer formulation/special use clinical research (where it exists), while the market projection is driven by:
• patent/generic economics (largely settled),
• guideline-directed utilization,
• resistance patterns and payer pressure,
• hospital and public health procurement cycles.

No single, consolidated “penicillin” R&D program is identifiable as a single drug trial stream comparable to a modern branded product.

---

What clinical trial updates are relevant for penicillin now?

Are there active late-stage penicillin trials that shape near-term monetization?

Penicillin is largely a standard-of-care generic. Trial activity that affects demand tends to be indirect (stewardship, resistance monitoring, comparative effectiveness of antibiotic strategies, and occasional formulation/administration innovations). The most investable clinical signals in this category are typically:

• antibiotic stewardship and de-escalation protocols that influence hospital prescribing volume of narrow-spectrum beta-lactams,
• regional resistance surveillance that shifts empiric selection away from or back toward penicillin-class agents,
• outcome studies for specific indications where penicillin remains guideline-supported (e.g., streptococcal pharyngitis and select syphilis regimens historically, plus selected beta-lactam susceptible infections).

Where does penicillin still show clinical relevance?

Penicillin retains clinical relevance where guidelines continue to support narrow-spectrum beta-lactams for susceptible pathogens:

• Group A Streptococcus infections (classically susceptible; penicillin G/V remains a reference standard in many protocols).
• Syphilis (historically penicillin is the core therapy; regimen selection depends on clinical context and guideline updates).
• Other streptococcal and susceptible bacterial infections where narrow beta-lactams are appropriate under stewardship.

---

How does resistance affect penicillin demand?

Does resistance erode penicillin’s clinical footprint?

Demand is shaped by the interaction of:

• intrinsic and acquired resistance (varies by organism),
• empiric prescribing patterns, and
• guideline thresholds used by hospitals and clinicians.

For a generic, the economic effect is usually not a dramatic “pipeline reroute” but a utilization shift:

• when resistance is low and susceptibility is high, penicillin use is maintained or expanded,
• when resistance or beta-lactam failure is common in a setting, prescribers switch toward broader beta-lactams or alternative classes.

---

What is the market structure for penicillin?

Is penicillin a branded market or a generic market?

Penicillin is a generic-dominant antibacterials category. The pricing power that characterizes branded oncology or specialty drugs does not apply. This means market outlook is driven by:

• procurement and contracting,
• manufacturing capacity and supply continuity,
• commodity-like pricing,
• hospital formulary decisions and guideline adherence.

What market segments matter commercially?

For penicillin-class antibacterials, demand is typically segmented by:

• formulation (oral vs injectable),
• healthcare setting (hospital vs outpatient),
• indication clusters (strep-related, syphilis and other susceptible infections, and limited niches for susceptible pathogens),
• geography (public procurement cadence, reimbursement structure, and local resistance patterns).

---

Market analysis: supply, pricing pressure, and volume drivers

What drives penicillin volume?

Volume is mainly driven by:

• guideline-supported indications where penicillin remains first-line or preferred narrow-spectrum therapy,
• stewardship-driven de-escalation from broad-spectrum beta-lactams toward narrow agents when susceptibility allows,
• public health programs for infections where penicillin remains the standard (notably syphilis treatment paradigms in many guideline sets).

What drives pricing and margins?

Margins are compressed by:

• multiple generics,
• procurement-based price competition,
• manufacturing and sterile/injectable compliance costs (more relevant for injectable penicillin G),
• import/export and tender cycle effects.

---

Forward projection: 3–5 year outlook

What is the most likely market trajectory for penicillin?

A realistic projection for penicillin-class antibacterials is:

• low single-digit growth or flat demand in many developed markets, with variability driven by resistance and stewardship intensity,
• greater variability in emerging markets due to procurement cycles, antibiotic policy enforcement, and supply stability.

Because penicillin is generic, the “projection” is better modeled as utilization stability with modest volume shifts, not as a “launch curve.”

Base-case projection (directional)

• Developed markets: stable to modest growth, constrained by already high penetration of penicillin in appropriate guideline indications and constrained by ongoing substitution toward broader agents in settings with higher failure rates.
• Emerging markets: modest growth where antibiotic access expands, but offset by policy swings, resistance trends, and affordability-driven selection.

Key risks to the projection

• accelerated substitution away from narrow penicillins in regions with increasing beta-lactam failure,
• supply disruptions in injectable lines (sterile manufacturing constraints),
• changes in public health guidance affecting regimens.

Key upside signals

• stewardship expansion that explicitly favors de-escalation to narrow-spectrum beta-lactams,
• stable susceptibility patterns in core indication organisms,
• improved formulary placement or procurement policies supporting narrow-spectrum agents.

---

Patent and exclusivity reality check

Does penicillin have meaningful patent-driven monetization today?

Penicillin’s original intellectual property is long expired. The commercial market behaves like a commodity generic with:

• ongoing life-cycle management through formulation patents (where they exist) rather than core drug compound exclusivity,
• regulatory focus on bioequivalence, quality, and manufacturing compliance.

As a result, investment theses are generally not built on patent cliffs or landmark exclusivity expansions; they are built on:

• manufacturing advantage,
• tender competitiveness,
• regulatory and supply reliability.

---

Clinical-to-commercial translation: what to watch

Which clinical signals most affect penicillin usage?

1. Guideline updates that reaffirm penicillin as first-line for specific infections.
2. Hospital stewardship metrics that track de-escalation from broad-spectrum beta-lactams to narrow agents.
3. Local surveillance data showing susceptibility stability for key pathogens.

Which non-clinical signals most affect revenue?

1. Procurement contracting trends for injectables (especially hospital-administered penicillin G).
2. Supply continuity and regulatory compliance events.
3. Tender price deflation versus inflation in manufacturing inputs.

---

Key Takeaways

• Penicillin is a generic, multi-member antibacterial class, not a single modern development-stage drug; therefore, “clinical trials updates” are best interpreted as stewardship and indication-specific evidence rather than a unified late-stage pipeline.
• The market is procurement-driven and price-competitive, with demand mainly shaped by guidelines, resistance patterns, and stewardship rather than new drug launches.
• Near-term market projection is best framed as utilization stability with modest shifts, with downside risk from resistance-driven prescribing substitution and upside from stewardship that increases narrow-spectrum beta-lactam use.
• Competitive advantage is most often determined by manufacturing reliability, regulatory execution, and tender economics, not patent leverage.

---

FAQs

1) Is “penicillin” one drug with one clinical trial program?

No. It is an antibacterial class spanning multiple members (commonly penicillin G and penicillin V) with distinct formulations and usage patterns. Trial activity tends to be indication- and strategy-specific rather than a single unified program.

2) What are the most important near-term clinical drivers for penicillin demand?

Guideline adherence for narrow-spectrum use, stewardship-driven de-escalation practices, and local resistance/susceptibility trends in key indication pathogens.

3) How does patent status affect penicillin’s market outlook?

Core penicillin IP is expired, so monetization relies on generic competitiveness, supply continuity, and tender-based pricing, not exclusivity.

4) What is the likely pricing behavior for penicillin?

Pricing is typically pressured by multi-generic competition and procurement tender dynamics, producing commodity-like economics and margin compression.

5) What would constitute a material upside catalyst for penicillin producers?

A measurable expansion in stewardship that increases narrow-spectrum penicillin utilization, plus stable susceptibility patterns and procurement policies that favor penicillin-class agents.

---

References

[1] World Health Organization. WHO Model List of Essential Medicines. Geneva: WHO.
[2] Centers for Disease Control and Prevention (CDC). Clinical Guidance for Group A Streptococcal Infections and Syphilis Treatment (beta-lactam use guidance). U.S. Department of Health and Human Services.
[3] IDSA (Infectious Diseases Society of America). Guidelines on Antibiotic Use and Stewardship (de-escalation and narrow-spectrum therapy principles). IDSA.
[4] European Centre for Disease Prevention and Control (ECDC). Antimicrobial Resistance surveillance and antibiotic consumption reporting frameworks. ECDC.